Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Stage
2.4. Snippet by Age Group
2.5. Snippet by Gender
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Underlying Conditions
3.1.1.2. Rising Awareness on NASH/MASH
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Limited Availability of Approved Drugs
3.1.2.2. Patient Compliance Issues
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Emerging Therapeutic Developments
3.1.3.2. Partnerships and Collaborations
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. North America Regulatory and Reimbursement Landscape
4.4. Porter’s Five Forces Analysis
4.5. Epidemiology Analysis
4.6. Pipeline Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
5. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, By Stage
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
5.1.2. Market Attractiveness Index, By Stage
5.2. Stage 4*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Stage 2-3
5.4. Stage 0-1
6. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, By Age Group
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
6.1.2. Market Attractiveness Index, By Age Group
6.2. Geriatrics*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Adults
6.4. Pediatrics
7. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, By Gender
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
7.1.2. Market Attractiveness Index, By Gender
7.2. Male*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Female
8. Competitive Landscape and Market Positioning
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. Company Profiles
Key market Players
9.1. Madrigal Pharmaceuticals*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
Emerging Companies
9.2. Novo Nordisk A/S
9.3. Boehringer Ingelheim International GmbH
9.4. 89bio, Inc.
9.5. Inventiva
9.6. Sagimet Biosciences
9.7. Akero Therapeutics, Inc.
LIST NOT EXHAUSTIVE
10. Assumption and Research Methodology
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. Appendix
11.1. About Us and Services
11.2. Contact Us